• Solid Biosciences filed a prospectus supplement for an at-the-market offering of up to USD 200 million of common stock via Jefferies.
• The sales program runs under a Form S-3 shelf registration statement that became effective May 27, 2025.
• About USD 85 million of common stock has already been sold under the prior prospectus supplement tied to the same sales agreement.
• The new prospectus supplement replaces the prior USD 85 million program for any future sales under the agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-338438), on August 06, 2026, and is solely responsible for the information contained therein.